The stock market-listed firm Silva Pharmaceuticals Limited held its 9th Extraordinary General Meeting (EGM) on December 1, 2025. A number of significant issues and recommendations pertaining to the company’s and all of its shareholders’ interests will be approved during the meeting, contingent upon approval from the Bangladesh Securities and Exchange Commission (BSEC) and other regulatory bodies.

A proposal to rename the business from “Silva Pharmaceuticals Limited” to “Silva Pharmaceuticals PLC” is one of the suggestions. Furthermore, modifications are being made to the Companies Act of 1994, as well as the associated Memorandum of Association and Articles. Remarkably, the updated Section 86 proposal shifts the requirement for the number of board members from “not fewer than 5 and not more than 7” to “not fewer than

In a recent board meeting, the company approved modifications to the design, drawings, and certain parts of the construction work for a new factory, originally planned as part of the capital raised through its IPO. The company has decided to move away from the existing design and instead adopt EU-GMP and cGMP compliance standards by procuring advanced technology equipment and machinery, ensuring the highest quality standards for pharmaceuticals and healthcare products.

The intended use of IPO funds has also been revised. The revised proposal to raise Tk 90 crore 33 lakh 32 thousand 700 has been approved. Of this, Tk 74 crore 24 lakh 12 thousand 400 will be used for civil construction of the new factory, Tk 5 crore for working capital, and the remaining Tk 2 crore 81 lakh 82 thousand 600 for machinery and equipment.

The EGM is scheduled for Tuesday, December 1, 2025, at 10:30 AM, and will be held through a hybrid system combining physical attendance and a digital platform. The record date has been set for Monday, December 1, 2025.